secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001082554-24-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85
----------------------------------------------------------------

- Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.
- Tyvaso products revenue $398.2M (+25% YoY), led by Tyvaso DPI growth from PH-ILD launch.
- Remodulin $147.3M (+16%), Orenitram $107.1M (+13%), Unituxin $51.7M (+17%).
- R&D expense rose 57% to $139.6M, driven by upfront licensing payments and organ manufacturing.
- Completed $300M tranche of $1B ASR; final $700M settlement expected in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000037/0001082554-24-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000037/uthr-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001082554-24-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer